Florida Atlantic University reports that melanoma cases and deaths in Florida run highest among the state's older adults, adding the most populous seniors' cohort in the U.S. to the list of groups carrying a disproportionate share of cutaneous melanoma burden.

The report centers on Florida — a state whose age structure makes it a natural observatory for skin cancer epidemiology. Florida's older residents have accumulated decades of ultraviolet exposure, and the FAU analysis places that population at the top of the state's melanoma statistics for both new diagnoses and deaths.

Why does the age skew matter for dermatology?

Melanoma outcome curves have shifted over recent decades, but age remains one of the most stubborn prognostic dividers in the disease. Older patients more often present with thicker tumors at diagnosis, and Breslow depth at detection remains a primary driver of staging and survival. Mortality figures concentrated in this cohort signal that late detection, not incidence alone, is shaping outcomes.

For practicing dermatologists, the FAU findings reinforce an already strong clinical argument:

• Total-body skin examinations should remain a default for patients over 65, particularly in high-UV geographies.
• Older men remain a historically underscreened group, and spouses or caregivers can be enlisted for lesion monitoring between visits.
• Any lesion report from an older patient — even a slow-changing pigmented lesion — warrants prompt evaluation rather than watchful waiting.

What does Florida's demographic profile add?

Florida hosts one of the largest populations of adults over 65 in the United States. A melanoma burden concentrated in that group carries outsized public-health weight: more affected patients per capita, more advanced presentations reaching clinics, and more deaths attributable to the disease than in demographically younger states.

The FAU report frames the state's older adults as the leading edge of the melanoma problem, not a peripheral subgroup. That framing matters for resource allocation — screening outreach, teledermatology access, and referral pathways for excision and pathology all scale with the size of the affected cohort.

How should clinicians respond?

The clinical implications track with established surveillance guidance rather than any new protocol. The FAU data underscore the value of age-targeted vigilance: dermatologists serving Florida-sized senior populations should weight their screening intensity accordingly, and primary-care referral networks in high-UV states should treat dermatologic referral for suspicious pigmented lesions in older adults as time-sensitive.

Patient education also carries weight here. Older adults came of age in an era before widespread sunscreen use and UV-awareness campaigns, and many underestimate the relevance of new sun-protection habits late in life. Counseling that lesion surveillance — not only prevention — remains effective at their age is a message clinicians can deliver in minutes.

What comes next?

Florida Atlantic University's findings add state-level evidence to the case for age-focused melanoma surveillance, and clinicians and public-health planners alike will be watching whether targeted screening programs for older adults in high-UV states can narrow the mortality gap the report identifies.